Results 221 to 230 of about 409,522 (315)

MicroRNA Profiles Targeting Angiopoietin-1, Angiopoietin-2, and TEK Receptor Tyrosine Kinase-2 Genes Associated with Angiogenesis in Proliferative Diabetic Retinopathy. [PDF]

Turk J Ophthalmol
Sancar H, Akaray İ, Özal SA, Ayaz L.
europepmc   +1 more source

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA

American Journal of Hematology, EarlyView.
ABSTRACT Frameshift mutations in exon 12 of nucleophosmin 1 (NPM1mut) are among the most common mutations in acute myeloid leukemia (AML) and have historically been considered favorable‐risk in the absence of FLT3‐ITD. In the European LeukemiaNet (ELN) 2024 risk‐classification for patients treated with hypomethylating agents plus venetoclax (HMA + VEN),
Fieke W. Hoff, Joshua F. Zeidner, Geeta Torlapati, Deedra Nicolet, Krzysztof Mrózek, Ying Huang, Alexander Li, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Maria R. Baer, Vu H. Duong, William G. Blum, Martha L. Arellano, Wendy Stock, Olatoyosi Odenike, Rebecca L. Olin, Catherine C. Smith, Gary J. Schiller, Emily K. Curran, Onyee Chan, Christine McMahon, Michael Hochman, Kieran Sahasrabudhe, Charles Foucar, Jesus Gonzalez‐Lugo, Brittany Knick Ragon, Shivani V. Handa, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja G. Marcus, Leonard Rosenberg, Brian J. Druker, Ross L. Levine, Amy Burd, Ashley O. Yocum, Uma M. Borate, Alice S. Mims, Ann‐Katrin Eisfeld, John C. Byrd, Yazan F. Madanat   +44 more
wiley   +1 more source

The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling. [PDF]

Int J Mol Sci
Jung MS, Choi WY, Zhang W, Barrera FN, Perkins RS.   +4 more
europepmc   +1 more source

Quizartinib in Combination With FLAG‐IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG‐QUIDA): A PETHEMA Phase I‐II Trial

American Journal of Hematology, EarlyView.
ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal, Javier Zambrano Márquez, Rebeca Rodríguez‐Veiga, Eduardo Rodríguez‐Arbolí, Juan Manuel Bergua‐Burgués, Susana Vives, Montserrat Arnán, Pilar Martínez Sánchez, Pilar Herrera‐Puente, Josefina Serrano‐López, Vicente Rubio, Inmaculada Marchante‐Cepillo, Marta Cervera‐Calvo, Andrés Novo García, Rosa Fernández Martín, Cristina Gil Cortés, Carlos Rodríguez‐Medina, Victor Noriega‐Concepción, Ana Alfonso‐Piérola, Carmen Loredo, María Antuña‐Casal, Blanca Boluda, Isabel Cano‐Ferri, Evelyn Acuña‐Cruz, Laura Torres‐Miñana, Joaquín Sánchez‐García, Cristina Bilbao, Maria Teresa Gómez‐Casares, David Martínez Cuadrón, Pau Montesinos   +29 more
wiley   +1 more source

The receptor tyrosine kinase ErbB2/HER2 governs CDK4 inhibitor sensitivity, timing, and irreversibility of the G1/S transition. [PDF]

J Biol Chem
Nagasato-Ichikawa A, Murakami K, Aoki K, Okada M.   +3 more
europepmc   +1 more source

Histidine Supplementation Stabilizes Hearing and Vision and Improves Growth in HARS1‐Related Autosomal Recessive Disorder Associated With Usher‐Like Symptoms

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Autosomal recessive HARS1‐related disorder (originally described as Usher syndrome type 3B) caused by a homozygous Y454S variant in the histidyl‐tRNA synthetase gene (HARS1) is characterized by progressive sensorineural hearing and vision loss and respiratory deterioration with risk for sudden death following febrile illnesses.
Victoria Mok Siu, Rosan Kenana, Rana Chakrabarti, Sarah D. P. Wilhelm, Joseph Andrews, Susan J. Leat, Christina Parker, Michael Miller, Leslie A. Nangle, Wendy McCaul, Ashfia Chowdhury, Natalie Hutchings, Ryan A. Adams, Lauren Guy, Mandy Rhody, Verena Juncal, Marisa I. Mendes, Desiree E. C. Smith, Gajja S. Salomons, Angelica A. Moresco, Daphne L. McCulloch, D. Holmes Morton, Ilka U. Heinemann, C. Anthony Rupar   +23 more
wiley   +1 more source

Discoidin domain receptor tyrosine kinase 2: A new perspective on microenvironment remodeling and targeted therapy of solid tumors (Review). [PDF]

Oncol Lett
Lu T, Guo H, Gong H, Ma Y, Tian Y, Zhang D.   +5 more
europepmc   +1 more source

Severe ADEM‐Like Neuroinflammatory Disease and Cerebrovascular Fragility With Recurrent Pseudoaneurysms and Moyamoya in a Familial Germline CBL Mutation: Expanding the Clinical Phenotype

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Heterozygous germline variants in CBL disrupt its function as a negative regulator of the Ras/MAPK pathway, classically predisposing to Juvenile myelomonocytic leukemia (JMML) and moyamoya. We describe two affected siblings carrying a paternally inherited CBL variant (c.1210 T> C, p.
Michal Bar‐Hakim, Anat Abramovich, Sara Via‐Dorembus, Gali Heimer, Bruria Ben‐Zeev, Etai Adam, Assaf A. Barg, Jonathan Roth, Basheer Sheick‐Yousif, Rony Beeri Berkowiz, Michal Feldon, Haim Bassan, Moran Hausman‐Kedem   +12 more
wiley   +1 more source

Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance. [PDF]

Front Cell Dev Biol
Wu W, Yang M, Qin J, Gui S, Zhang Z, Zhang Y, Du Y.   +6 more
europepmc   +1 more source

Review of the Molecular and Developmental Basis of Myhre Syndrome, Bench Research

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre syndrome (MS) is a connective‐tissue disorder within the acromelic dysplasia spectrum. It is characterized by congenital craniofacial, skeletal, cutaneous anomalies, respiratory, cardiovascular along with intellectual disability, deafness, and progressive fibrosis.
Camille Viaut, Valerie Cormier‐Daire
wiley   +1 more source